SPAC1142.09 Antibody

What is SPAC1142.09 and why is it significant in research?

SPAC1142.09 is a gene designation in Schizosaccharomyces pombe (fission yeast) encoding a protein of interest in cellular biology studies. Antibodies targeting this protein are valuable tools for investigating its expression, localization, and function within cellular contexts. The significance lies in understanding fundamental cellular processes in eukaryotic systems, as S. pombe serves as an important model organism with conserved pathways relevant to human biology. Research with SPAC1142.09 antibodies enables visualization of protein dynamics, interaction studies, and functional characterization through various immunological techniques.

What are the available types of SPAC1142.09 antibodies for research applications?

Similar to other research antibodies, SPAC1142.09 antibodies are typically available in polyclonal and monoclonal formats. Polyclonal antibodies recognize multiple epitopes on the SPAC1142.09 protein, providing strong signal amplification but potentially higher background . Monoclonal antibodies target specific epitopes with high specificity but may be more sensitive to epitope masking or denaturation . For recombinant approaches, antibodies may be developed as fragments or with specific fusion tags to enhance functionality. The choice between these formats depends on the intended application, with considerations for specificity, sensitivity, and reproducibility requirements.

How should I validate a SPAC1142.09 antibody before experimental use?

Proper validation of SPAC1142.09 antibodies requires a multi-step approach:

• Positive and negative controls: Test the antibody on samples known to express or lack SPAC1142.09 (wild-type vs. knockout strains)

• Cross-reactivity assessment: Evaluate potential cross-reactivity with related proteins through Western blot analysis

• Application-specific validation: Confirm performance in your specific application (Western blot, immunoprecipitation, immunofluorescence)

• Reproducibility testing: Ensure consistent results across multiple experiments and protein preparations

For more advanced validation, consider:

• siRNA knockdown experiments to confirm specificity

• Mass spectrometry analysis of immunoprecipitated proteins

• Epitope mapping to identify the specific binding region

Lack of thorough validation can lead to misleading results and wasted resources in downstream experiments.

What are the optimal conditions for using SPAC1142.09 antibodies in Western blot analysis?

For Western blot applications with SPAC1142.09 antibodies, consider the following methodological approach:

When troubleshooting, address non-specific bands by increasing blocking time or adjusting antibody concentration. For weak signals, consider longer exposure times, increased antibody concentration, or alternative extraction methods to ensure target protein solubilization .

How can I optimize immunoprecipitation protocols using SPAC1142.09 antibodies?

For effective immunoprecipitation of SPAC1142.09 and its interacting partners:

• Cell lysis optimization: Use gentle lysis conditions (e.g., 150mM NaCl, 1% NP-40 or 0.5% Triton X-100) to preserve protein-protein interactions

• Pre-clearing step: Pre-clear lysate with protein A/G beads to reduce non-specific binding

• Antibody binding: Incubate 1-5 μg of SPAC1142.09 antibody with 500-1000 μg of protein lysate (4°C, 2-4 hours)

• Bead capture: Add protein A/G beads and incubate overnight at 4°C with gentle rotation

• Washing optimization: Perform 4-5 washes with decreasing salt concentration to balance specificity and sensitivity

• Elution conditions: Elute with gentle conditions (non-reducing SDS buffer at 70°C) to maintain complex integrity

For co-immunoprecipitation studies targeting SPAC1142.09 interaction partners, consider crosslinking approaches with formaldehyde or DSP (dithiobis(succinimidyl propionate)) to stabilize transient interactions before cell lysis .

What are the best practices for immunofluorescence microscopy using SPAC1142.09 antibodies?

For optimal immunofluorescence results with SPAC1142.09 antibodies:

• Fixation method: 4% paraformaldehyde (15 minutes, room temperature) preserves most epitopes; alternatively, methanol fixation (-20°C, 10 minutes) for certain epitopes

• Permeabilization: 0.2% Triton X-100 in PBS (10 minutes) for cytoplasmic/nuclear proteins

• Blocking: 3% BSA in PBS with 0.1% Tween-20 (1 hour, room temperature)

• Primary antibody: Dilute SPAC1142.09 antibody 1:100 to 1:500 (determine empirically), incubate overnight at 4°C

• Secondary antibody: Fluorophore-conjugated secondary (Alexa Fluor series recommended) at 1:500 dilution (1 hour, room temperature)

• Nuclear counterstaining: DAPI (1 μg/ml, 5 minutes)

• Mounting: Anti-fade mounting medium to prevent photobleaching

For co-localization studies, select secondary antibodies with well-separated emission spectra to avoid bleed-through. Include appropriate controls: secondary-only control, isotype control, and known positive/negative samples to validate specificity .

How can epitope mapping improve the utility of SPAC1142.09 antibodies in research?

Epitope mapping provides critical insights for enhancing SPAC1142.09 antibody applications:

• Peptide array analysis: Synthesize overlapping peptides spanning the SPAC1142.09 sequence and probe with the antibody to identify the specific binding region

• Mutagenesis approach: Generate point mutations in recombinant SPAC1142.09 to identify critical residues for antibody binding

• Hydrogen-deuterium exchange mass spectrometry: Map structural epitopes based on differential solvent accessibility in antibody-bound versus free protein

Understanding the precise epitope location offers several research advantages:

• Prediction of antibody cross-reactivity with related proteins

• Assessment of epitope conservation across species for cross-species applications

• Determination if the epitope is accessible in various experimental conditions (native vs. denatured)

• Design of blocking peptides for specificity validation experiments

Researchers can use epitope information to select antibodies targeting different regions for complementary approaches or to explain discrepancies between different antibodies targeting the same protein .

What strategies can overcome challenges in detecting post-translational modifications of SPAC1142.09?

Detecting post-translational modifications (PTMs) of SPAC1142.09 requires specialized approaches:

• Phosphorylation detection:

  • Use phospho-specific antibodies when available

  • Employ phosphatase treatment controls to confirm specificity

  • Consider Phos-tag™ SDS-PAGE for mobility shift detection

  • Use titanium dioxide enrichment before mass spectrometry analysis

• Ubiquitination detection:

  • Express His-tagged ubiquitin and perform nickel column purification

  • Include deubiquitinase inhibitors in lysis buffers

  • Use antibodies specific to K48 or K63 linkages to distinguish degradation vs. signaling

• SUMOylation and other modifications:

  • Employ denaturing conditions during immunoprecipitation to maintain modifications

  • Use SUMO-specific proteases as controls

  • Consider site-directed mutagenesis of potential modification sites

The sensitivity of detection can be enhanced by first enriching for the modified form of SPAC1142.09 through immunoprecipitation with the general antibody, followed by detection with modification-specific antibodies .

How can I design ChIP-seq experiments using SPAC1142.09 antibodies for chromatin-associated studies?

For ChromatIn Immunoprecipitation sequencing (ChIP-seq) with SPAC1142.09 antibodies:

• Crosslinking optimization:

  • Standard: 1% formaldehyde for 10 minutes at room temperature

  • For weak or transient interactions: Add protein-protein crosslinkers (DSG, EGS) before formaldehyde

• Sonication parameters:

  • Target fragment size: 200-500 bp

  • Optimize cycles and amplitude based on cell type

  • Verify fragmentation by agarose gel electrophoresis

• Immunoprecipitation specifics:

  • Pre-clear chromatin with protein A/G beads

  • Use 3-5 μg of SPAC1142.09 antibody per ChIP reaction

  • Include IgG control and input samples (5-10%)

• Controls and validation:

  • Perform ChIP-qPCR on known targets before sequencing

  • Include spike-in controls for normalization

  • Validate peaks with alternative antibody or tagged protein

• Data analysis considerations:

  • Use appropriate peak calling algorithms (MACS2 recommended)

  • Perform motif enrichment analysis

  • Consider differential binding analysis between conditions

For factor-specific optimizations, adjust salt concentration in wash buffers (150-500 mM NaCl) based on binding strength and perform pilot experiments to determine optimal chromatin-to-antibody ratios .

How do I address non-specific binding issues with SPAC1142.09 antibodies?

When encountering non-specific binding with SPAC1142.09 antibodies, implement this systematic troubleshooting approach:

• Blocking optimization:

  • Increase blocking time (2-3 hours or overnight)

  • Test alternative blocking agents (5% milk, 5% BSA, commercial blockers)

  • Add 0.1-0.3% Tween-20 to reduce hydrophobic interactions

• Antibody dilution and incubation:

  • Increase antibody dilution (1:2000 to 1:5000)

  • Reduce incubation temperature (4°C)

  • Add competing proteins (0.1-0.5% BSA in antibody dilution)

• Washing stringency:

  • Increase wash buffer salt concentration (150mM to 500mM NaCl)

  • Add detergents (0.1-0.5% Triton X-100)

  • Extend washing time and number of washes

• Pre-adsorption strategy:

  • Pre-incubate antibody with blocking peptide or knockout cell lysate

  • Use beads pre-coated with irrelevant proteins to capture non-specific antibodies

• Physical separation:

  • For immunofluorescence: Use confocal microscopy to minimize out-of-focus signal

  • For Western blot: Use gradient gels for better protein separation

Document all optimization steps systematically, changing only one parameter at a time to identify the most effective approach for your specific application .

What is the optimal approach to quantify SPAC1142.09 protein levels across different experimental conditions?

For accurate quantification of SPAC1142.09 protein levels:

• Western blot quantification:

  • Use fluorescent secondary antibodies rather than chemiluminescence for better linearity

  • Include a dilution series of recombinant protein or positive control for standard curve

  • Normalize to multiple housekeeping proteins (β-actin, GAPDH, tubulin)

  • Utilize image analysis software with background subtraction capabilities

  • Perform technical triplicates and biological replicates

• ELISA-based quantification:

  • Develop a sandwich ELISA using two antibodies targeting different SPAC1142.09 epitopes

  • Generate standard curves with recombinant protein

  • Validate with knockout/knockdown controls

  • Assess matrix effects with spike-in recovery experiments

• Flow cytometry quantification:

  • Use calibration beads with known antibody binding capacity

  • Implement consistent gating strategies across experiments

  • Include isotype controls for background subtraction

  • Report data as molecules of equivalent soluble fluorochrome (MESF)

For all methods, statistical analysis should include tests for normality before applying parametric tests. When comparing across conditions, consider using fold-change relative to control rather than absolute values to account for experiment-to-experiment variation .

How can I resolve contradictory results when using different SPAC1142.09 antibodies?

When faced with conflicting results from different SPAC1142.09 antibodies:

• Epitope comparison:

  • Map the epitopes recognized by each antibody

  • Determine if post-translational modifications might affect epitope accessibility

  • Consider if protein conformation influences antibody binding

• Validation approaches:

  • Perform knockdown/knockout experiments with each antibody

  • Use tagged recombinant SPAC1142.09 as a control

  • Validate with orthogonal methods (mass spectrometry)

• Experimental condition analysis:

  • Assess if buffer conditions affect epitope exposure differently

  • Determine if fixation methods alter antibody binding sites

  • Evaluate if protein complexes mask certain epitopes

• Technical considerations:

  • Compare lot-to-lot variation between antibody batches

  • Assess if antibody storage conditions affect performance

  • Evaluate antibody age and potential degradation

To resolve contradictions, consider that different antibodies may recognize different isoforms, conformations, or modification states of SPAC1142.09. The apparent discrepancy may actually reveal biologically relevant information about protein regulation or processing. Document and report all antibody details (catalog number, lot, dilution) when publishing to ensure reproducibility .

How can SPAC1142.09 antibodies be adapted for super-resolution microscopy?

Optimizing SPAC1142.09 antibodies for super-resolution microscopy requires specialized approaches:

• STED microscopy optimization:

  • Select bright, photostable fluorophores (Atto647N, Abberior STAR dyes)

  • Use F(ab')2 fragments for reduced linkage error

  • Increase primary antibody concentration (2-3x standard IF protocol)

  • Implement two-color STED with careful chromatic aberration correction

• STORM/PALM considerations:

  • Select photoswitchable fluorophores (Alexa Fluor 647, mEos)

  • Use oxygen scavenging buffer systems (GLOX, MEA)

  • Optimize labeling density for accurate localization

  • Implement drift correction with fiducial markers

• Sample preparation refinements:

  • Use thinner (10-15 μm) sections for reduced background

  • Consider expansion microscopy protocols for improved resolution

  • Implement post-fixation after antibody labeling

  • Mount samples in specialized imaging media with matched refractive index

• Quantitative validation:

  • Calculate localization precision through cluster analysis

  • Perform Fourier ring correlation for resolution estimation

  • Use nearest neighbor analysis for co-localization studies

These advanced techniques can resolve SPAC1142.09 localization with 20-50 nm precision, potentially revealing previously undetectable protein distributions or interactions within cellular structures .

What strategies enable multiplexed detection of SPAC1142.09 and interacting proteins?

For simultaneous detection of SPAC1142.09 and its interaction partners:

• Antibody-based multiplexing:

  • Conjugate antibodies directly with different fluorophores to avoid species cross-reactivity

  • Implement sequential immunostaining with intermediate stripping/blocking steps

  • Use zenon labeling technology for same-species antibodies

  • Consider tyramide signal amplification for weak signals

• Proximity ligation assay (PLA):

  • Detect protein-protein interactions within 40 nm proximity

  • Use SPAC1142.09 antibody paired with antibodies against suspected interaction partners

  • Quantify interaction signals through automated spot counting

  • Include appropriate controls (single antibody, non-interacting protein pairs)

• Mass cytometry (CyTOF):

  • Label antibodies with distinct metal isotopes

  • Measure up to 40 parameters simultaneously

  • Analyze with dimensionality reduction algorithms (tSNE, UMAP)

  • Cluster cells based on SPAC1142.09 expression and interacting proteins

• Cyclic immunofluorescence:

  • Image 4-5 proteins, then strip antibodies

  • Repeat with new antibody sets (up to 40 proteins on same sample)

  • Align images computationally between cycles

  • Create high-dimensional spatial maps of protein networks

These approaches enable comprehensive analysis of SPAC1142.09 in its native protein interaction network context, providing insights into function and regulation .

How can I apply biophysical models to analyze SPAC1142.09 antibody binding kinetics?

Advanced biophysical analysis of SPAC1142.09 antibody-antigen interactions:

• Surface plasmon resonance (SPR):

  • Determine kon and koff rates separately

  • Calculate equilibrium dissociation constant (KD)

  • Analyze binding under various buffer conditions

  • Assess the impact of temperature on binding kinetics

• Bio-layer interferometry (BLI):

  • Real-time, label-free measurement of binding

  • Requires less sample than SPR

  • Establish epitope binning through competitive binding assays

  • Determine binding stoichiometry

• Isothermal titration calorimetry (ITC):

  • Measure thermodynamic parameters (ΔH, ΔS, ΔG)

  • Determine binding stoichiometry directly

  • No labeling or immobilization required

  • Suitable for difficult-to-immobilize proteins

• Mathematical modeling considerations:

  • Apply biophysical models similar to those for viral escape from polyclonal antibodies

  • Fit binding data to appropriate kinetic models (1:1, bivalent, heterogeneous ligand)

  • Calculate apparent affinity in complex biological samples

  • Model epitope accessibility in different protein conformations

For SPAC1142.09 antibodies, these analyses provide insights into specificity, sensitivity, and optimization of experimental conditions. Higher affinity antibodies (KD in nM range) are generally preferred for immunoprecipitation and chromatin immunoprecipitation, while moderate affinity antibodies may be suitable for applications requiring signal amplification .

What are the emerging technologies that will enhance SPAC1142.09 antibody research?

Several cutting-edge technologies are poised to transform SPAC1142.09 antibody research:

• Single-cell proteomics:

  • Antibody-based single-cell Western blots

  • Microfluidic approaches for single-cell protein analysis

  • Integration with transcriptomic data for multi-omic insights

  • Spatial resolution of protein expression in tissues

• Engineered antibody formats:

  • Nanobodies and single-domain antibodies for improved penetration

  • Bispecific antibodies for co-detection of interaction partners

  • Intrabodies for live-cell tracking of SPAC1142.09

  • Photoactivatable antibodies for targeted studies

• Artificial intelligence applications:

  • Deep learning for automated image analysis

  • Prediction of cross-reactivity and epitope accessibility

  • Design of optimal antibody pairs for multiplex detection

  • Integrated analysis of multi-dimensional data

• In situ structural biology:

  • Cryo-electron tomography with antibody labeling

  • Correlative light and electron microscopy (CLEM)

  • Integration of structural and functional data

  • Visualization of SPAC1142.09 in native cellular context

These technologies will enable more precise, quantitative, and comprehensive studies of SPAC1142.09, potentially revealing new functions and regulatory mechanisms that are currently inaccessible with conventional approaches .

How can research datasets for SPAC1142.09 antibodies be standardized for reproducibility?

To enhance reproducibility in SPAC1142.09 antibody research:

• Comprehensive antibody reporting:

  • Document complete antibody metadata (source, catalog number, lot, RRID)

  • Specify validation methods with positive and negative controls

  • Report detailed protocols with exact buffer compositions

  • Share raw image data in public repositories

• Standardized validation workflows:

  • Implement minimum validation requirements (Western blot, immunoprecipitation, immunofluorescence)

  • Document validation in knockout/knockdown systems

  • Verify specificity with orthogonal methods

  • Register antibodies in validation databases

• Data sharing practices:

  • Deposit raw data in appropriate repositories (Protein Atlas, Antibodypedia)

  • Implement FAIR principles (Findable, Accessible, Interoperable, Reusable)

  • Use electronic lab notebooks with version control

  • Include detailed methods in supplementary materials

• Community standards development:

  • Participate in antibody validation initiatives

  • Contribute to reference datasets for benchmarking

  • Adopt standardized reporting guidelines

  • Implement authentication practices for key reagents